Dr Trina Racine possesses a PhD in Microbiology and Immunology from Dalhousie University (Halifax, Nova Scotia, Canada) and is currently the Director of Vaccine Development at VIDO. Upon completion of her PhD, Dr. Racine joined the Special Pathogens Program at the National Microbiology Laboratory (NML), part of the Public Health Agency of Canada. While at the NML Dr. Racine worked on the development of vaccines and therapeutics for various emerging and re-emerging infectious diseases, including Ebola, Zika and MERS. Dr. Racine coordinated clinical trials and provided diagnostic support to the Ebola outbreak in West Africa in 2014-2016. Prior to joining VIDO, Dr. Racine was a Scientific and Regulatory Affairs Consultant for GeneOne Life Science, Inc., a South Korean based biopharmaceutical company. As Director of Vaccine Development at VIDO, Dr. Racine is responsible for guiding the development, manufacturing, and clinical/field testing of VIDO’s internal products using a Stage Gate process. Dr. Racine is also responsible for VIDO’s Vaccine Development Centre (VDC), a pilot scale, Containment Level 3 capable, GMP biomanufacturing facility capable of producing veterinary vaccines to North American licensure and human vaccines to Phase II clinical trials.
· How has the respiratory season evolved? Co-circulation of respiratory pathogens, duration of the respiratory disease season, what are the dominant pathogens?
· Where are we seeing innovation in vaccines for respiratory diseases?
· How are we progressing with prophylactic antibodies, combination & universal respiratory vaccine approaches?
· Uptake for Flu, RSV, COVID vaccines. Are we seeing vaccine fatigue from a crowded schedule?
· Globally evolving regulatory and policy landscape